The invention relates to a method of producing a decellularized tissue scaffold. The invention also relates to a tissue scaffold produced by said method. In particular, porcine tissue scaffolds. The method comprises reduced levels of anionic detergent, and avoids the use of animal derived protease inhibitors to produce a tissue scaffold with favourable properties.

A method for producing an epithelial cell sheet, comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) a ROCK inhibitor.

Provided is a composition for treating cartilage injury lesion that is combined with a concentrated bone marrow aspirate and applied to a cartilage injury lesion, that has flowability when applied to the cartilage injury lesion, and that contains a monovalent metal salt of alginic acid. Thereby, a novel composition for treating cartilage injury lesion that can be used to restore and/or regenerate cartilage tissue is provided.

Disclosed are a functionalized biological matrix material, a preparation method therefor and use thereof, which belong to the technical field of medical materials. In the present invention, by means of the hybridization of a biological matrix material with 3-sulfopropyl methacrylate, the cross-linking and functionalization of the biological matrix material are achieved at the same time. A specific method comprises modifying carbon-carbon double-bond structures such as allyl, methallyl in a biological matrix material, immersing the biological matrix material in an aqueous solution containing 3-sulfopropyl methacrylate, and finally performing cross-linking and functionalization on the biological matrix material by means of radical polymerization, and using the biological matrix material to prepare materials such as valves. The present invention achieves multi-site and long-range cross-linking of a biological matrix material by means of a polymer network, and at the same time introduces corresponding functional functional groups so as to achieve functionalization of the biological matrix material.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

Described herein are tissue grafts derived from the placenta with improved physical and biological properties. In one aspect, the tissue graft includes a first membrane comprising Wharton's jelly laminated with amnion, chorion, or a combination thereof. The presence of Wharton's jelly in the grafts enhances the performance of allograft amniotic-derived, caderivic allograft, xenograft, or alloplast soft tissue substitutes.

Methods of making articles with a 3D printer using biomaterials that retain physical properties and biological activity are discussed. Methods can include providing a crosslinkable material and a biomaterial to a 3D printer, and crosslinking the materials to form an implant. Biomaterials can include, among other things, bone, or tissue.

A method for micro-tissue encapsulation of cells includes coating a tissue scaffold stamp with an extracellular matrix compound; depositing the tissue scaffold stamp onto a thermoresponsive substrate; seeding the tissue scaffold stamp with a cell culture; incubating the cell culture on the tissue scaffold stamp at a temperature that is specified, wherein the cell culture forms a cell patch that is attached to the extracellular matrix compound; removing the thermoresponsive substrate by lowering the temperature; removing the tissue scaffold stamp from the cell patch to form a micro-tissue structure by dissolving the tissue scaffold stamp in a solvent; folding the micro-tissue structure by suspending the micro-tissue in the solvent to enable the cell patch to fold the micro-tissue structure; collecting the folded micro-tissue structure from the solvent; and administering the folded micro-tissue structure to an organism.

Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an esophagus of a subject. These methods include injecting submucosally into the esophagus of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the esophagus, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the esophagus; and c) a stiffness of about 10 to about 400 Pascal (Pa). The ECM hydrogel is not a urinary bladder ECM hydrogel.

The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α). The present invention also relates to methods for producing the biomaterial and uses thereof.